Results 111 to 120 of about 143,948 (293)

Serotonin regulates prostate growth through androgen receptor modulation [PDF]

, 2017
Serotonin regulates prostate growth through androgen receptor modulationAging and testosterone almost inexorably cause benign prostatic hyperplasia (BPH) in Human males. However, etiology of BPH is largely unknown.
A Morgentaler, AT Cockett, AV Pechersky, AV Sarma, BG Timms, CA Wilson, CL Dakin, CS Cooper, DJ Walther, EJ Siddiqui, G Bartsch, GR Cunha, GR Cunha, JE McNeal, JE McNeal, JE Morley, JF Murray, JH Lipschutz, K Izumi, KB Egan, L Aaron, L Santamaría, L Santamaría, M Krieg, M Matsuda, MA Haghsheno, MA Islam, N Dizeyi, P Zhang, R Deanesly, R Martín, RH Sayed, RO Roberts, SJ Berry, SJ Berry, SM Harman, TM Nicholson, X Zhang   +37 more
core   +3 more sources

Prostate blood flow in patients with benign prostatic hyperplasia complicated by urine retention

RUDN Journal of Medicine, 2012
Benign prostatic hyperplasia is the most frequent disease among middle and old aged men and connected with increasing of lifetime of men. The incidence of the disease is 42% to 87% in different aged groups.
E A Atamanova, V P Avdoshin, M I Andryukhin, V V Chugaev   +3 more
doaj  

Recanalization of prostatic artery chronic total occlusion prior to prostatic artery embolization

Radiology Case Reports, 2019
Urinary obstruction secondary to benign prostatic hyperplasia is a late manifestation of the disease, and a poor prognostic sign for responding to conservative therapies.
Adam N. Plotnik, MBBS MSc MMed FRANZCR EBIR, Dustin G. Roberts, BS, Ravi N. Srinivasa, MD, Justin P. McWilliams, MD   +3 more
doaj   +1 more source

Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia

Therapeutic Advances in Urology, 2018
Rezum is a minimally invasive transurethral water vapour therapy for benign prostatic enlargement which uses thermal energy for treatment. The short-term results show it to have good outcomes with a potential for outpatient-based treatment preserving ...
J. Westwood, R. Geraghty, Patrick Jones, Bhavan Prasad Rai, B. Somani   +4 more
semanticscholar   +1 more source

Single‐Cell Sequencing Reveals That CD4+ T Cells Eliminate Senescent Prostate Epithelium to Delay Progression of Benign Prostatic Hyperplasia

Aging Cell, EarlyView.
Senescent BPH epithelial cells secrete CXCL13 to recruit CD4+ T cells via CXCR5. Cytotoxic CD4+ T cells eliminate senescent cells through MHC‐II–dependent recognition. Tregs suppress, while B cells show minimal effect. This immune axis modulates senescent cell clearance and may influence BPH progression.
Zheng Li, Xiaofei Wang, Zhifu Liu, Senmao Li, Zhenan Zhang, Chenchen Huang, Yixiao Liu, Xingxing Tang, Jiaen Zhang, Peimin Zhou, Ying Gan, Yu Fan, Yisen Meng, Kaiwei Yang, Shuai Hu, Qian Zhang, Wei Yu   +16 more
wiley   +1 more source

Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH) [PDF]

, 2015
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110594/1/bju12802 ...
Anderson, Barry, Barry, Burke, Crawford, Cuticchia, D'Agostino, Dorresteijn, Emberton, Flanigan, Hong, Jacobsen, Kaplan, Kent, Kok, Lowe, Martin, Maserejian, McConnell, Parsons, Roehrborn, Roehrborn, Roehrborn, Roehrborn, Slawin, Slawin, Steyerberg, Trachtenberg   +27 more
core   +1 more source

TRANSCRIPTION FACTOR BRN-3α AND PROSTATE CANCER, RELATION WITH HORMONE RECEPTORS AND AKT/M-TOR SIGNALING PATHWAY ACTIVATION

Сибирский онкологический журнал, 2018
Introduction. The transcription factor Brn-3α (product of the POU4F1) plays a significant role in carcinogenesis. The purpose of the study was to investigate Brn-3α, AR, ERα expressions in tissues of benign prostatic hyperplasia and prostate cancer as ...
L. V. Spirina, A. K. Gorbunov, I. V. Kondakova, E. M. Slonimskaya, E. A. Usynin   +4 more
doaj   +1 more source

An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications

The American Journal on Addictions, EarlyView.
Abstract Background Opioid use disorder (OUD) imposes a significant socioeconomic burden, highlighting the need for new interventions. Objective This study investigated whether exposure to 5‐alpha reductase inhibitors (5αRIs) is associated with a lower risk of developing OUD.
Abdelrahman G. Tawfik, Tyler Lister, Ainhoa Gomez‐Lumbreras, Randall T. Peterson, Marco Bortolato, Daniel C. Malone   +5 more
wiley   +1 more source

Prostate artery EmbolisAtion Safety and efficacY: Preliminary and foLlow‐Up urodynamic Studies (P‐EASY PLUS)

BJU International, EarlyView.
Objective To assess the efficacy of prostate artery embolisation (PAE) in the management of obstructive benign prostatic hyperplasia (BPH) by conducting formal urodynamic studies. Methods Patients with symptomatic BPH underwent baseline assessments, including urodynamic evaluation, followed by PAE. Follow‐up International Prostate Symptom Scores (IPSS),
Nicholas Brown, Sepinoud Firouzmand, Anthony Kiosoglous, Stephanie Castree, Duncan Walker, Rhiannon McBean, Boon Kua, Troy Gianduzzo, Rachel Esler, Peter Campbell, Joseph Schoeman, John Yaxley   +11 more
wiley   +1 more source

Prostatic Artery Embolization as a New Option in the Treatment of Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia – Current Evidence

Acta Clinica Croatica, 2018
Prostatic artery embolization is a minimally invasive endovascular treatment that improves lower urinary tract symptoms in men with benign prostatic hyperplasia.
Luka Novosel, Ivan Pezelj, Igor Tomašković, Dijana Zadravec, Boris Ružić   +4 more
doaj   +1 more source